681260-50-4

Usage

Uses

Used in Medicinal Chemistry:
[2-Methyl-6-(trifluoromethyl)pyridin-3-yl]methanol is used as a reagent or intermediate in organic synthesis for the production of pharmaceuticals. Its unique structure and properties make it a promising candidate for the development of new drugs with improved efficacy and selectivity.
Used in Agrochemicals:
In the agrochemical industry, [2-Methyl-6-(trifluoromethyl)pyridin-3-yl]methanol is used as a building block for the synthesis of various agrochemicals. Its incorporation into the molecular structure of these compounds can enhance their biological activity and selectivity, leading to more effective and environmentally friendly products.
Used in Material Science:
[2-Methyl-6-(trifluoromethyl)pyridin-3-yl]methanol may also find applications in material science, where its unique structure can be utilized to develop new materials with specific properties. These materials could have potential uses in various industries, such as electronics, coatings, or adhesives.
Used as a Reference Standard in Analytical Methods:
Due to its distinct functional groups, [2-Methyl-6-(trifluoromethyl)pyridin-3-yl]methanol can be used as a reference standard in analytical methods. It aids in the identification and quantification of compounds containing similar functional groups, ensuring accurate and reliable results in various analytical techniques.

Upstream product

• 205582-88-3 methyl 2-methyl-6-(trifluoromethyl)nicotinate 
• 261635-93-2 2-methyl-6-(trifluoromethyl)pyridine-3-carboxylic acid 
• 380355-65-7 ethyl 2-methyl-6-(trifluoromethyl)pyridine-3-carboxylate 

Downstream Products

• 917481-91-5 6-chloro-5-(4-chlorophenyl)-2-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-4-(pyridin-4-yl)-pyridazin-3(2H)-one 
• 917969-46-1 8-bromo-7-(4-chlorophenyl)-2-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 917969-39-2 4-(8-bromo-2-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)benzonitrile 
• 917968-89-9 3-((7-(4-chlorophenyl)-3-oxo-8-(pyridin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)methyl)-2-methyl-6-(trifluoromethyl)pyridine 1-oxide 
• 917969-50-7 3-((7-(4-chlorophenyl)-3-oxo-8-(pyridin-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)methyl)-6-(trifluoromethyl)picolinoyl chloride 

Relevant academic research and scientific papers

Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties

Several strategies have been employed to reduce the long in vivo half-life of our lead CB1 antagonist, triazolopyridazinone 3, to differentiate the pharmacokinetic profile versus the lead clinical compounds. An in vitro and in vivo clearance data set revealed a lack of correlation; however, when compounds with 5% free fraction were excluded, a more predictable correlation was observed. Compounds with log P between 3 and 4 were likely to have significant free fraction, so we designed compounds in this range to give more predictable clearance values. This strategy produced compounds with desirable in vivo half-lives, ultimately leading to the discovery of compound 46. The progression of compound 46 was halted due to the contemporaneous marketing and clinical withdrawal of other centrally acting CB1 antagonists; however, the design strategy successfully delivered a potent CB1 antagonist with the desired pharmacokinetic properties and a clean off-target profile.

2-Alkyl/alkenyl substituted pyridine C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as highly potent TRPV1 antagonists

A series of 2-alkyl/alkenyl pyridine C-region derivatives of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides were investigated as hTRPV1 antagonists. Multiple compounds showed excellent and stereospecific TRPV1 antagonism with better potency than previous lead 2. Among them, compound 15f demonstrated a strong analgesic profile in a rat neuropathic pain model and blocked capsaicin-induced hypothermia in a dose-dependent manner. Docking analysis of (S)-15f with our hTRPV1 homology model provided insight into its specific binding mode.

Triazolopyridine cannabinoid receptor 1 antagonists

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.

NOVEL HERBICIDES

Compounds of formula I: wherein R1, R2, R3, R4, m, R5, R6, n and Y are as defined in claim 1; or N-oxides, salts and optical isomers thereof. Furthermore, the present invention relates to processes for preparing compounds of formula (I), to herbicidal compositions comprising them and to methods of using them to control plants or to inhibit plant growth.

Triazolopyrimidine cannabinoid receptor 1 antagonists

The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.